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Abstract 
Background: Although a number of Plasmodium vivax proteins have been identified, few have been investigated 
as potential vaccine candidates. This study characterized the Plasmodium vivax merozoite surface antigen 180 
(PvMSA180, PVX_094920), a novel P. vivax antigenic protein.
Methods: The target gene was amplified as four overlapping domains (D1, D2, D3 and D4) to enable expression 
of the recombinant protein using cell‑free and bacterial expression systems. The recombinant PvMSA180 proteins 
were used in protein microarrays to evaluate the humoral immune response of 72 vivax‑infected patients and 24 
vivax‑naïve individuals. Antibodies produced in mice against the PvMSA180‑D1 and ‑D4 domains were used to assess 
the subcellular localization of schizont‑stage parasites with immunofluorescence assays. A total of 51 pvmsa180 
sequences from 12 countries (41 sequences from PlasmoDB and 6 generated in this study) were used to determine 
the genetic diversity and genealogical relationships with DNAsp and NETWORK software packages, respectively.
Results: PvMSA180 consists of 1603 amino acids with a predicted molecular mass of 182 kDa, and has a signal pep‑
tide at the amino‑terminus. A total of 70.8% of patients (51/72) showed a specific antibody response to at least one 
of the PvMSA180 domains, and 20.8% (15/72) exhibited a robust antibody response to at least three of the domains. 
These findings suggest that PvMSA180 is targeted by the humoral immune response during natural infection with P. 
vivax. Immunofluorescence analysis demonstrated that PvMSA180 is localized on the merozoite surface of schizont‑
stage parasites, and pvmsa180 sequences originating from various geographic regions worldwide showed low 
genetic diversity. Twenty‑two haplotypes were found, and haplotype 6 (Hap_6, 77%) of pvmsa180 was detected in 
isolates from six countries.
Conclusions: A novel P. vivax surface protein, PvMSA180, was characterized in this study. Most of P. vivax‑infected 
patients had specific antibodies against particular antigenic domains, indicating that this protein is immunogenic in 
naturally exposed populations. Genetic analysis of worldwide isolates showed that pvmsa180 is less polymorphic than 
other well‑known candidates and that some haplotypes are common to several countries. However, additional stud‑
ies with a larger sample size are necessary to evaluate the antibody responses in geographically separated popula‑
tions, and to identify the function of PvMSA180 during parasite invasion.
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Background
Malaria is a public health problem in countries in which 
it is endemic [1]. In 2015, the number of cases and deaths 
was 214 million and 438,000, respectively [2]. Plasmo-
dium vivax causes 50% of all malaria cases globally [3], 
and is prevalent in the tropics and subtropics [4]. A 
malaria vaccine shows promise for controlling malaria 
[5]; however, the antigenic diversity and immune-evasion 
ability of Plasmodium has hampered vaccine develop-
ment [6]. Molecules expressed on the merozoite surface, 
such as apical membrane antigen-1 (AMA1), merozoite 
surface protein-1 (MSP1), and Duffy binding protein, 
have been the focus of vaccine development efforts [7].
Bioinformatic and genome analysis of P. vivax have led 
to the identification of malaria antigens, few of which 
have been investigated as vaccine candidates [8–10]. 
MSPs, such as MSP-1, MSP-9, MSP-4 and MSP-5, have 
been identified as vaccine candidates [11]. Some hypo-
thetical proteins have been identified as vaccine can-
didates based on coiled coil structure [10]. Moreover, 
several proteins of P. vivax that are expressed on the 
surface or in apical organelles, including MSPs, rhoptry-
associated membrane antigen, glycosylphosphatidylino-
sitol (GPI)-anchored micronemal antigen and AMA1, 
have been proposed as vaccine candidates due to their 
involvement in merozoite invasion or the longevity of 
the antibody response [12–16]. Due to the limitations of 
P. vivax in  vitro culture systems, fewer surface proteins 
have been identified in this pathogen than in P. falcipa-
rum. In fact, a number of P. vivax surface proteins have 
been identified based on their orthologues in P. falcipa-
rum [9, 10, 15, 17], and the antibody responses to them 
have been investigated [18–20].
One of hypothetical proteins, named P. vivax mero-
zoite surface antigen 180 (PvMSA180) was previously 
identified [21]. Of the 96 P.  vivax blood-stage pro-
teins, 18 (including PvMSA180) elicited robust anti-
body responses [21]. Thus, this study has characterized 
PvMSA180, which is immunogenic in naturally exposed 
populations, and determined its subcellular localization 
in P. vivax.
Methods
Sample and serum information
Blood samples were collected from 72 patients in 2012 
in the Shwe Kyin area of Myanmar (mean age, 24.5 years; 
range, 18–42 years). The patients were confirmed to have 
P. vivax malaria using the malaria rapid diagnostic test 
(SDFK80; Standard Diagnostics, Gyeonggi, Korea) and 
microscopy. Samples were centrifuged and the serum 
was separated. Serum samples from 24 healthy malaria-
naïve individuals residing in non-endemic areas in the 
Republic of Korea (ROK) were also collected and used 
as controls.
Amplification of full‑length pvmsa180
Parasite genomic DNA was extracted using a Qiagen 
DNA Extraction Kit (Hilden, Germany). The pvmsa180 
(PVX_094092) sequence was obtained from PlasmoDB 
(http://plasmodb.org/). Full-length pvmsa180 was ampli-
fied from five Myanmar and one South Korean iso-
late using the forward primer 5′-GATGACGACACAA 
ACAAAAGGG-3′ and reverse primer 3′-CGCGGCGTAG 
TTGATGTG-5′. Full-length pvmsa180 was amplified 
by PCR using high-fidelity Thermococcus kodakaraen-
sis (KOD) DNA polymerase (Toyobo, Osaka, Japan) 
under the following conditions: 2.0  μL DNA template, 
0.4 U KOD DNA polymerase, 0.25  mM of each primer 
and 500  μM of each dNTP, in a final volume of 20  mL. 
The cycling conditions were 94 °C for 2 min, followed by 
35 cycles at 94 °C for 15 s, at 58 °C for 30 s, at 68 °C for 
4.5 min, and a final extension at 68 °C for 10 min.
Recombinant PvMSA180 expression
PvMSA180 was divided into four fragments and 
expressed using a cell-free system. The four fragments 
of pvmsa180 were amplified under the aforementioned 
conditions, with the exception of a final extension for 
1.5 min, using the following In-fusion primers:
D1-F: 5′-GGGCGGATATCTCGAGGATGACGACAC 
AAACAAAAGGG-3′ and D1-R: 5′-GCGGTACCCGG 
GATCCTTACCCGACATAGTACATTTGCTCA-3′; 
D2-F: 5′-GGGCGGATATCTCGAGAAGCTGCACCCA 
AAGAAGC-3′ and D2-R: 5′-GCGGTACCCGGGATCC 
TTACATCTTCTCGTACAACAGCATATCA-3′; D3-F: 
5′- GGGCGGATATCTCGAGGTGCTGGAGCTAGTAA 
ATAATGATATG-3′ and D3-R: 5′- GCGGTACCCGG 
GATCCTCAAAAGGCGCACTTCAAACTCA-3′; D4-F: 
5′-GGGCGGATATCTCGAGGTGCGAAAAGAAAAT 
GGAC-3′ and D4-R: 5′-GCGGTACCCGGGATCCTCAC 
GCGGCGTAGTTGATGTG-3′. Underlining indicates 
the 15 base pair (bp) homologous vector site; italicized, 
bolded, and underlined text indicates the XhoI and 
BamHI sites. The PCR products were cloned into the 
pEU-E01-His-Tev-N2 vector (Cell-Free Sciences, Mat-
suyama, Japan) using the In-fusion cloning kit (Clon-
tech, Palo, Alto, CA, USA), and expressed using a wheat 
germ cell-free system (Cell-Free Sciences) [15, 22–24]. 
The crude recombinant proteins were used for immuno-
screening of serum samples. Recombinant PvMSA180-
D1 and PvMSA180-D4 proteins were expressed in 
Escherichia coli. PvMSA180–D1 was expressed using the 
pGEX-4T-2 expression vector (GE Healthcare, Upsala, 
Sweden) with a glutathione S transferase (GST) tag, and 
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PvMSA180-D4 was expressed using the pET-28a (+) 
expression vector (Invitrogen, Carlsbad, CA, USA) with 
a His-tag. The target domains were amplified using In-
fusion primers and High-Fidelity DNA Polymerase (Toy-
obo), and cloned into the appropriate expression vectors. 
Positive clones confirmed by DNA sequencing analysis 
were transformed into E. coli BL21(DE3) cells (Invitro-
gen). When the cultures reached an optical density of 
0.6, expression of the recombinant D1 and D4 fragments 
was induced by addition of 0.1 and 0.3 mM isopropyl-β-
d-thiogalactopyranoside, respectively. The GST-tagged 
proteins were purified using glutathione Sepharose 4B 
(GE Healthcare) and 6 His-tagged proteins using nickel-
nitrilotriacetic acid (Ni–NTA) (Qiagen), according to the 
manufacturer’s instructions. The purity of the recom-
binant proteins was evaluated by sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blotting.
SDS‑PAGE and Western blotting
The recombinant PvMSA180 proteins were resolved on 
13% SDS-PAGE gels under reducing conditions, and then 
electrotransferred to 0.45  µm PVDF membranes (Mil-
lipore, Billerica, MA, USA) in semi-dry transfer buffer 
(50 mM Tris, 190 mM glycine, 3.5 mM SDS, 20% metha-
nol) at a constant current of 360  mA for 40  min using a 
semi-dry blotting system (ATTO Corp., Tokyo, Japan). 
Recombinant PvMSA180-D1 and PvMSA180-D4 (1  µg 
each) and PvDBP-RII (0.5 µg) were used to assay antibody 
responses. The membranes were blocked in 5% skim milk 
and then incubated with a primary anti-GST antibody 
(1:10,000), anti-pentahistidine antibody (1:2000), mouse 
immune serum, or pooled patient serum (1:100), followed 
by incubation with a secondary IRDye® goat anti-mouse 
(1:10,000 dilution) or IRDye® goat anti-human (1:20,000) 
(LI-COR® Bioscience, Lincoln, NE, USA) antibody. An 
Odyssey infrared imaging system and the accompanying 
software (LI-COR® Bioscience) were used for data analysis.
Protein microarray
Slides were coated with amine solution [21] and used 
to screen the serum of 72 vivax-infected patients and 
24 healthy individuals by protein microarray. The crude 
recombinant proteins expressed using the wheat germ 
cell-free system were applied in duplicate and incu-
bated for 2  h at 37  °C, followed by blocking in 5% BSA 
in phosphate-buffered saline (PBS) with 0.1% Tween 20 
(PBS-T) and incubation for 1 h at 37  °C. Diluted serum 
(1:25) was added to a slide harbouring recombinant pro-
teins and incubated for 1  h, followed by addition of an 
Alexa 647-conjugated goat-anti-human IgG (10  µg/mL, 
Invitrogen). Then slides were imaged using a fluorescence 
scanner (ScanArray Express, PerkinElmer, Boston, MA, 
USA). The cut-off value was equal to the mean fluores-
cence intensity (MFI) plus two standard deviations (SDs) 
of the negative samples. Normalized MFI values were 
calculated from the MFI/cut-off values.
Production of mice antibody
Female BALB/c mice at 6–8  weeks of age (DBL, Seoul, 
ROK) were injected intraperitoneally with 30 µg recom-
binant PvMSA180-D1 and -D4 in PBS with complete 
Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO) in a 
final volume of 100  µL, and subsequently boosted with 
incomplete Freund’s adjuvant. Three mice were injected 
three times with each of the D1 and D4 fragments of 
PvMSA180 at 2-week intervals. Sera were collected 
2 weeks after the final boost. All the animal experimen-
tal protocols were approved by the Institutional Ethics 
Committee and were conducted in accordance with the 
Ethical Guidelines for Animal Experiments of Kangwon 
National University (ROK).
Immunofluorescence assays
Plasmodium vivax parasites were collected from patients 
with malaria in Thailand and spotted onto eight-well 
glass slides. The slides were fixed in ice-cold acetone for 
10 min, dried, and blocked in 5% BSA in PBS-T at 37 °C 
for 30 min. Then the slides were incubated (dual-labelled) 
with rabbit anti-PvMSP1-19 (1:50 dilution), rabbit anti-
PvDBP (1:50 dilution), rabbit anti-PvRAMA (1:50 dilu-
tion), and mouse anti-PvMSA180 (1:100) as primary 
antibodies at 37 °C for 1 h. Next, the slides were stained 
with Alexa Fluor 568-conjugated anti-rabbit IgG or Alexa 
Fluor 488-conjugated goat anti-mouse IgG as second-
ary antibodies (Invitrogen), and nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) at 
37  °C for 30  min. The slides were mounted in ProLong 
Gold antifade reagent (Invitrogen) and visualized under 
oil immersion using a confocal laser scanning micro-
scope (FV200Olympus, Tokyo, Japan) equipped with 
20× dry and 60× oil objectives. Images were captured 
using the FV10-ASW 3.0 viewer software.
Sequence diversity and haplotype analysis of pvmsa180 
in isolates obtained worldwide
The pvmsa180 sequences obtained in this study were 
compared to those of 46 isolated worldwide in the Plas-
moDB database. Pvmsa180 sequences from 12 coun-
tries (South Korea, Myanmar, Salvador, Peru, Colombia, 
Mexico, Thailand, Brazil, India, Papua New Guinea, 
North Korea, and China) were included in the analysis 
(Additional file  1). All the raw sequences were analysed 
and trimmed using the SeqMan software, Lasergene 
ver. 7.0 (DNASTAR). Sequences were aligned using the 
CLUSTAL-W program in MegAlign Lasergene ver. 7.0 
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(DNASTAR) and exported in FASTA format. Sequence 
diversity (π), defined as the average number of nucleo-
tide differences per site between two sequences, number 
of polymorphic sites was determined using the DNAsp 
ver. 5.0 software. The relationships among the haplotypes 
of pvmsa180 were evaluated with the me-dian-joining 
method using the NETWORK software ver. 4.6.1.2. 
(Fluxus Technology Ltd., Suffolk, UK). The C-terminus 
amino acid sequences of PvMSA180 were also separately 
aligned using Clustal W2 to assess the sequence homol-
ogy among two human and simian malaria parasites.
Statistical analysis
Simple scatter regression was applied to construct a stand-
ard curve using SigmaPlot (Systat Software Inc., San Jose, 
CA, USA). Data were analysed using GraphPad Prism 
(GraphPad, Software, San Diego, CA, USA). The Student’s 
t test was used to assess differences between means. Val-
ues of p < 0.05 were considered statistically significant. The 
MeV software (MultiExperiment Viewer, http://www.tm4.
org/mev.html) was used to visualize the antibody responses 
of individual patients to the PvMSA180 domains.
Results
Schematic structure of PvMSA180
The protein consists of 1603 amino acids with a pre-
dicted molecular mass of 182  kDa, and lacks a trans-
membrane domain and GPI anchor, as determined using 
the deduced amino acid sequence of P. vivax (Sal-1). 
The cysteine residues are adjacent to the C-terminus 
domain. Proteins were expressed without a signal pep-
tide. The D1 domain of PvMSA180 (207–307  amino 
acids) from worldwide isolates contains a polymorphic 
region (Fig. 1a). In addition, the C-terminus sequence of 
PvMSA180 has high sequence homology with the human 
(P. falciparum) and two simian (Plasmodium knowlesi 
and Plasmodium cynomolgi) malaria parasites. The 
amino acid alignment revealed 70% amino acid identity 
among human and simian malaria parasites (Fig. 1b).
Expression of recombinant PvMSA180 proteins
The four domains of PvMSA180 were expressed using a 
wheat germ cell-free system, resulting in a single band 
of  ~50 to 75  kDa; all the domains were predicted to 
be  <50  kDa (Fig.  2a). PvMSA180-D1 was successfully 
Fig. 1 Schematic of recombinant PvMSA180 expression. a Schematic of PvMSA180. The D1 (amino acids [aa] 28–401), D2 (aa 385–800), D3 (aa 
785–1180), and D4 (aa 1163–1603) domains were expressed using cell‑free and bacterial expression systems. SP signal peptide, P polymorphic 
region (aa 290–307). b Clustal alignment of the C‑terminus sequence of MSA180 of Plasmodium vivax (Pv), Plasmodium falciparum (Pf ), Plasmodium 
knowlesi (Pk), and Plasmodium cynomolgi (Pc). Red bars indicate the conserved aa in the four Plasmodium species, green bars in three species, sky‑blue 
bars in two species, and dark‑blue bars in one species. Asterisks denote cysteine residues conserved in the four Plasmodium species
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expressed as a 70.3  kDa GST fusion protein, and 
PvMSA180-D4 was expressed in E. coli as a 6× His-
tagged, 52.7 kDa recombinant protein (Fig. 2b, c). SDS-
PAGE and Western blotting showed that recombinant 
PvMSA180-D1 and PvMSA180-D4 have molecular 
weights of  ~80 and  ~60  kDa, respectively (Fig.  2b, c). 
Purified PvMSA180-D1 and PvMSA180-D4 were used to 
immunize Balb/c mice with the aim of generating poly-
clonal antibodies.
Recognition of recombinant PvMSA180 proteins
To confirm the immunoreactivity of PvMSA180, puri-
fied recombinant PvMSA180-D1 and PvMSA180-D4 
were incubated with pooled sera of vivax-infected 
patients. Bands at  ~80 and  ~60  kDa for PvMSA180-
D1 and PvMSA180-D4, respectively, were detected by 
Western blotting (Fig.  2d). In addition, to confirm anti-
body production in mice against the D1 and D4 domains 
of PvMSA180, recombinant proteins were subjected to 
Western blotting using polyclonal anti-PvMSA180-D1 
and PvMSA180-D4 antibodies (Fig. 2d).
Humoral immune response to PvMSA180
The humoral immune response of 72 vivax-infected 
patients and 24 healthy individuals to the four domains 
of PvMSA180 was evaluated by protein microarray. Sera 
from vivax-infected patients showed significantly higher 
reactivity than that from healthy individuals (Fig.  3a, 
p < 0.0001). The number of healthy individuals and vivax-
infected patients showing a serum immune response 
to PvMSA180 was determined (Table  1). The antibody 
response to the four domains did not differ markedly. 
However, antibodies to PvMSA180 showed positive reac-
tivity against PvMSA180, and there was no correlation 
between the humoral immune response and patient age 
or the presence of parasitaemia.
PvMSA180 localized on the merozoite surface
The subcellular localization of PvMSA180 was eval-
uated by immunofluorescence analysis using an 
anti-PvMSA180-D1 antibody. Dual-labelled immu-
nofluorescence assays were performed using an 
anti-PvMSA180-D1 antibody together with an anti-
PvMSP1-19 (merozoite surface marker) (Fig.  4a, 
b), anti-PvDBP (microneme marker) (Fig.  4c), or 
anti-PvRAMA (rhoptry marker) (Fig.  4d) antibody 
as controls. The anti-PvMSA180-D1 (N-terminus) 
and PvMSA180-D4 (C-terminus) antibodies specifi-
cally reacted with anti-PvMSP1-19 antibodies in the 
merozoites of mature schizonts. This suggests that 
PvMSA180 is localized on the merozoite surface, but 
not in the rhoptry or microneme.
Nucleotide diversity and haplotype analysis
The 51 pvmsa180 sequences exhibited a low level of diver-
sity (π = 0.00080 ± 0.00012). Alignment of the pvmsa180 
sequences revealed 34 (0.84%) polymorphic and 3985 
(99.15%) invariant sites. The polymorphic region (i.e., 
879–927 nucleotides) contained the highest nucleotide 
sequence diversity (π = 0.02196 ± 0.0099). The haplotype 
network analysis of 51 pvmsa180 sequences from world-
wide isolates identified 22 unique haplotypes with mod-
erate haplotype diversity (Hd =  0.8698). One haplotype 
(Hap_6) was shared (Fig. 5) by 17 isolates from Colombia 
(n = 5), Mexico (n = 2), Peru (n = 4), Myanmar (n = 2), 
Salvador (n = 1), and Thailand (n = 3). None of the other 
haplotypes were shared (Fig. 5). The haplotypes obtained 
in this study are listed in Additional file 2.
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Fig. 2 Expression of recombinant PvMSA180. a Expression of recom‑
binant domains of PvMSA180 in a wheat germ cell‑free expression 
system. Arrowheads indicate the four domains of PvMSA180. D1 
domain 1, D2 domain 2, D3 domain 3, and D4 domain 4. b Expression 
and purification of PvMSA180‑D1 (GST‑fused) and D4 (His‑tagged) in 
E. coli. c Recombinant PvMSA180‑D1 and D4 were probed with anti‑
GST and anti‑His antibodies under reducing conditions. Arrowheads 
indicate the PvMSA180‑D1 (~80 kDa) and D4 (~60 kDa) bands. d 
Antibody recognition of PvMSA180‑D1 and D4 compare to PvDBP‑RII 
recombinant proteins using pooled vivax‑patient sera (lane P), malaria 
naïve healthy sera (lane H), mouse immune serum (lane M), and anti‑
GST or anti‑His antibody (lane R)
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Fig. 3 Human IgG response to the four domains of PvMSA180 by protein microarray. a Crude recombinant PvMSA180 was probed with sera from 
vivax‑infected patients (P) and naïve healthy individuals (H). The total prevalence of anti‑PvMSA180 IgG significantly differed between patients and 
naïve healthy individuals. *p < 0.01; ***p < 0.0001 by Student’s t‑test. Bars indicate means ± standard deviation. b IgG response to the four domains 
of PvMSA180 in individual patients. Red and green bars indicate positive and negative reactivity, respectively, in each domain. For total reactivity, red 
bar indicates 3–4 positive domains; green indicates 1–2 positive domains, and blue indicates the negative domains. The serial numbers of the serum 
samples are shown on the vertical line
Table 1 Rate of seropositivity to the four domains of PvMAS180 of vivax-infected patients and naïve controls
a Seropositivity rate: percentage of positive malaria-patient samples
b Normalized MFI: mean fluorescence intensities were divided by the cut-off value +2 standard deviations above the mean fluorescence intensity of the malaria-naïve 
samples
c Sero negative rate: percentage of malaria-naïve samples
d Confidence intervals
e Difference in the total IgG prevalence for each antigen between vivax patients and healthy individuals was calculated by the Student’s t-test. A value of P < 0.05 was 
considered statistically significant
Domains No. of patient samples (n) Normalized 
MFIb
95% CId No. of healthy samples (n) Normalized 
MFIb
95% CId p valuee
Posi‑
tive
Nega‑
tive
Total (%)a Posi‑
tive
Nega‑
tive
Total (%)c
I 32 40 72 (44.4) 1.02 33.5–55.9 1 23 (22) 95.8 0.61 79.8–99.3 p < 0.0001
II 12 60 72 (16.7) 0.79 9.8–26.9 1 23 (22) 95.8 0.64 79.8–99.3 p < 0.01
III 29 43 72 (40.3) 1.02 29.7–51.8 1 23 (22) 95.8 0.70 79.8–99.3 p < 0.0001
IV 30 42 72 (41.7) 0.98 30.9–53.2 0 24 (24) 100 0.64 86.2–100 p < 0.0001
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Discussion
Genomics, proteomics, and transcriptomics have been 
used to identify target antigens in Plasmodium spp. [10, 
21–24]. This has resulted in the identification of proteins 
expressed by infected red blood cells on the surface or in 
apical organelles; however, few such P. vivax proteins have 
been reported [13]. A small number of promising merozo-
ite antigens has been investigated as vaccine candidates, 
some of which have shown partial efficacy in clinical trials 
[13]. MSPs are of interest for the development of vaccines 
as well as drugs that inhibit blood-stage replication of P. 
falciparum [25–27]. In this study, PvMSA180, a novel sur-
face protein of P. vivax, was characterized.
Most of the cysteine residues are in the C-ter-
minus domain of PvMSA180, which has no trans-
membrane domain or GPI-anchor. The results of the 
immunofluorescence assay showed that the PvMSA180 
protein is localized on the merozoite surface; thus, it 
might be categorized as being peripherally associated 
with the surface of P. vivax merozoites as it lacks trans-
membrane domains and a GPI-anchor [13]. PvMSA180 
orthologs in other species have a conserved domain at 
the C-terminus that shows  ~70% sequence similarity 
with simian malaria parasites (P. knowlesi and Plasmo-
dium chabaudi), but a lower level of identity to Plasmo-
dium falciparum. Nevertheless, P. vivax is genetically, 
phenotypically, and biologically more similar to P. 
chabaudi and P. knowlesi than to P. falciparum [28–31]. 
Unlike erythrocyte-binding ligand (ebl) and reticulocyte-
binding protein (rbp), which are crucial for the invasion 
of erythrocytes by P. vivax, P. knowlesi, and P. chabaudi, 
the function of msa180 in other species is unclear.
Fig. 4 Localization of PvMSA180 in mature schizont‑stage parasites. Schizont‑stage parasites were dual‑labelled with antisera against PvMSP1‑19 
(merozoite surface marker) (a and b), PvDBP (microneme marker) (c), or PvRAMA (rhoptry marker) (d). Nuclei are stained with DAPI in the merged 
images. Scale bar represents 5 µm. DIC differential interference contrast
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The amplification and sequence analysis of clinical iso-
lates from diverse geographic regions showed the pres-
ence of a short polymorphic domain at the N-terminus 
region of pvmsa180. The polymorphic region of invasion 
genes is considered under immune selection pressure [32] 
and plays a role in protective immunity against clinical 
isolates [32–34]. However, in this study, the polymorphic 
and conserved domains of PvMSA180 showed simi-
lar immunogenicity. Furthermore, 20.8% of the patients 
(15/72) showed a robust antibody response to more 
than three domains of PvMSA180, and only 30% did not 
respond to any of the antigens (Fig. 3b). The development 
of a malaria vaccine based on merozoite surface antigens 
has been hindered by their high sequence diversity [35, 
36]. In this study, haplotype network analysis resulted in 
the detection of 22 haplotypes, 1 of which (Hap_6, 17/22) 
was shared by six countries. However, a greater number 
of samples are required to confirm this finding, as serum 
samples from only Myanmar and the ROK were used in 
this study. These data will facilitate the development of a 
subunit vaccine based on the domains conserved among 
strains isolated worldwide. The functional activity of this 
antibody could not be performed due to the limitation of 
P. vivax culture system. It remains to be determined as 
further study in the future.
Conclusions
In this study, a novel P. vivax surface protein, PvMSA180, 
was identified. Its immunogenicity in a naturally exposed 
population suggests that it elicits a humoral immune 
response, and its localization suggests that it may be 
involved in merozoite attachment to, and invasion of red 
blood cells. However, further functional and biological 
investigations of PvMSA180 protein are required prior 
to its development as a subunit vaccine. Genetic analy-
sis indicated that the gene is less polymorphic than other 
well-known candidates and a haplotype common to six 
countries was identified.
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Fig. 5 Median‑joining networks of pvmsa180 haplotypes from isolates worldwide. Genealogical haplotype network showing the relationships 
among 22 pvmsa180 haplotypes in 51 sequences obtained from P. vivax isolates from 12 countries. H‑number, haplotype number. The size of the 
circles represents the haplotype frequencies and unnumbered circles indicate a single haplotype. Geographical haplotypes are indicated by the 
colour key. Small red nodes are hypothetical median vectors created by the program to connect sampled haplotypes into a parsimonious network. 
The distances between nodes are arbitrary
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